Population Pharmacokinetics of Risperidone and Paliperidone in Schizophrenia: A Systematic Review

Population Pharmacokinetics of Risperidone and Paliperidone in Schizophrenia: A Systematic Review

<b>Background:</b> The primary treatment of schizophrenia is pharmacotherapy with antipsychotic agents, such as risperidone and paliperidone. Population pharmacokinetic (PopPK) modelling plays a crucial role in optimising therapy by predicting of plasma concentrations, therapeutic effica...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ana Carrascosa-Arteaga, Ricardo Nalda-Molina, Patricio Más-Serrano, Amelia Ramon-Lopez
Format:	Article
Language:	English
Published:	MDPI AG 2025-05-01
Series:	Pharmaceuticals
Subjects:	schizophrenia antipsychotic agents risperidone paliperidone palmitate drug monitoring pharmacokinetics
Online Access:	https://www.mdpi.com/1424-8247/18/5/698
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature review
by: Zhang L, et al.
Published: (2016-01-01)

Dynamics of Clinical Manifestations and Social Functioning in Schizophrenia: A Non-interventional Observational Study of Paliperidone Palmitat Dosage Forms
by: Aleksandr M. Reznik, et al.
Published: (2024-12-01)

Head-to-Head Comparison of UHPLC-MS/MS and Alinity C for Plasma Analysis of Risperidone and Paliperidone
by: Francisco José Toja-Camba, et al.
Published: (2024-10-01)

A case report of exacerbation of extrapyramidal symptoms following the switch from risperidone to paliperidone during valproate therapy
by: Emi Hata, et al.
Published: (2025-01-01)

Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study
by: Li H, et al.
Published: (2015-12-01)

Efficacy and safety of paliperidone palmitate 1-month formulation (PP1M) for schizophrenia in southwestern China
by: Lian Gou, et al.
Published: (2025-04-01)

Clinical effectiveness of paliperidone palmitate 3‐monthly and 1‐monthly as monotherapy in patients with schizophrenia: A retrospective cohort study based on the Medicaid claims database
by: Chih‐Lin Chiang, et al.
Published: (2024-12-01)

Successful treatment with olanzapine and aripiprazole of a schizophrenic patient who developed priapism after switching from risperidone to paliperidone
by: Saki Kawahara, et al.
Published: (2024-12-01)

Population Pharmacokinetic Modeling of TV-46000, a Risperidone Long-Acting Subcutaneous Antipsychotic for the Treatment of Patients with Schizophrenia
by: Itay Perlstein, et al.
Published: (2025-03-01)

Long-Term Symptomatic and Functional Remission with Paliperidone Palmitate 6-Monthly Treatment in Schizophrenia: A 3-Year Post-Hoc Analysis
by: Hamilton JM, et al.
Published: (2025-06-01)

Treatment Persistence of Paliperidone Palmitate 3‐Month in Patients With Schizophrenia: A Japan Medical Data Center Claims Database Analysis
by: Akihide Wakamatsu, et al.
Published: (2025-06-01)

The effectiveness of paliperidone palmitate at the stage of stabilizing treatment of schizophrenia in the outpatient department. Clinical observation
by: M. R. Bagautdinov
Published: (2020-01-01)

One-Year Evaluation of Paliperidone Palmitate 6-Monthly: Satisfaction and Perceived Effectiveness Among Patients, Relatives, and Clinicians
by: Manchado Perero S, et al.
Published: (2025-05-01)

Risperidone-induced Premature Ventricular Complexes in Psychosis: A Case Report
by: Javed A Siddiqui, et al.
Published: (2023-06-01)

A cross-sectional study to analyze the pattern of pharmacotherapy and its associated factors among patients with schizophrenia
by: B. S. Abhishree, et al.
Published: (2024-12-01)

Patient social function and quality of life in schizophrenia: focus on paliperidone palmitate
by: E. V. Grigorieva
Published: (2018-07-01)

Retrospective analysis of hospitalization rates in patients with schizophrenia 12 months before and 12 months after the switch on once-monthly long-acting injectable paliperidone palmitate
by: Totić-Poznanović Sanja, et al.
Published: (2023-01-01)

Long-term effectiveness, adherence and safety of twice-yearly paliperidone-palmitate long acting-injectable in patients with schizophrenia in Europe: 2-year mirror-image data from the paliperdone-2 per year study (P2Y)
by: Sofía Manchado Perero, et al.
Published: (2025-03-01)

Efficacy of paliperidone palmitate once-monthly (PP1M) in improving social functioning and reducing caregiver burden in patients with schizophrenia: a six-month follow-up study
by: Ling Dong, et al.
Published: (2025-07-01)

The maintenance of modified electroconvulsive therapy combined with risperidone is better than risperidone alone in preventing relapse of schizophrenia and improving cognitive function
by: Ying Yang, et al.

Gender-stratified 9-month comparison of paliperidone extended-release tablets and paliperidone palmitate injection in schizophrenia
by: Zheng Lan, et al.
Published: (2025-05-01)

A hybrid model for predicting response to risperidone after first-episode psychosis
by: Giovany Oliveira Costa, et al.
Published: (2025-03-01)

Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study
by: Shi C, et al.
Published: (2016-08-01)

Deterioration of COVID-19 vaccine efficacy by antipsychotic medications in schizophrenia patients
by: Takashi Kusunoki, et al.
Published: (2025-05-01)

Comparative cardiovascular outcomes of aripiprazole vs. risperidone in patients with type 2 diabetes and schizophrenia: a retrospective cohort study
by: Yi-Ting Yeh, et al.
Published: (2025-07-01)

Comparative Efficacy of Lorazepam and Risperidone in Hospitalized Cannabis-induced Psychotic Disorder
by: Arshdeep Jhalli, et al.
Published: (2024-02-01)

An Evaluation of the Subcutaneous Depot Release of TV-46000, A Novel Long-Acting Injectable (LAI) Formulation of Risperidone, Under Extreme Conditions in Dogs, Minipigs and Humans
by: Lilach Steiner, et al.
Published: (2025-01-01)

A multidimensional assessment of adverse events associated with paliperidone palmitate: a real-world pharmacovigilance study using the FAERS and JADER databases
by: Siyu Lou, et al.
Published: (2025-01-01)

Memantine abrogates testicular dysfunction induced by risperidone in rats with a potential role of ERK1/2-Nrf2-caspase-3 signaling pathway
by: Reham H. Mohyeldin, et al.
Published: (2025-04-01)

MRI-based insights into brain structural and functional alterations in schizophrenia treated with risperidone
by: Hangyu Li, et al.
Published: (2025-06-01)

Cardiac Considerations in Treatment of Schizophrenia: A Case Report Highlighting the Use of Long-acting Injection Paliperidone Palmitate Depot in Schizophrenia Patient with Comorbid Wolff-Parkinson-White Syndrome
by: Suparna Kumar, et al.
Published: (2025-02-01)

Post Mortem Paliperidone Blood Concentrations Following Long-Acting Injectable Treatments
by: Pietro Zuccarello, et al.
Published: (2025-05-01)

Ekbom Syndrome Management in Elderly Patients: Challenges in Risperidone Titration and Treatment Adherence
by: Florina Madalina Mindru, et al.
Published: (2025-03-01)

Risperidone-induced Myoclonus in a Young Patient with Schizophrenia
by: Aman Naqvi, et al.
Published: (2025-01-01)

Bioequivalence study of tablet forms of risperidone, olanzapine and quetiapine in healthy volunteers
by: V. V. Pisarev, et al.
Published: (2013-04-01)

Age-related changes of superoxide dismutase activity in patients with schizophrenia
by: Đorđević Vladimir V., et al.
Published: (2017-01-01)

Activation of osteoblast ferroptosis by risperidone accelerates bone loss in mice models of schizophrenia
by: Hongyan Fan, et al.
Published: (2025-01-01)

Chemical and Toxicological Diagnosis of Acute Poisoning with Clozapine, Olanzapine, Quetiapine and Risperidone
by: M. V. Belova, et al.
Published: (2020-10-01)

Flash Chromatography Application for Risperidone Purification
by: G. S. Trush, et al.
Published: (2015-08-01)

Changes in the pharmacokinetics of lurasidone in a pregnant woman with schizophrenia
by: Mihoko Kawai, et al.
Published: (2024-12-01)